Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, Queens, New York, USA.
Cancer Res. 2011 Jun 1;71(11):3735-8. doi: 10.1158/0008-5472.CAN-11-0375. Epub 2011 May 24.
The phenomenon of multidrug resistance (MDR) has decreased the hope for successful cancer chemotherapy. The ATP-binding cassette (ABC) transporter superfamily is the largest transmembrane family. The overexpression of ABC transporters is a major determinant of MDR in cancer cells both in vitro and in vivo. Unfortunately, until recently, most of the strategies used to surmount ABC-transporter-mediated MDR have had limited success. An ideal modulator of MDR would be one that has a low liability to induce toxicity and alter the pharmacokinetic profile of antineoplastic drugs. Sildenafil, an inhibitor of cGMP-specific phosphodiesterase type 5, was found to significantly reverse ABC-transporter-mediated MDR. Our results indicate that sildenafil has differential inhibitory effects on ABC transporters: It significantly decreases the efflux activity of ABCB1 and ABCG2, but has no significant effects on ABCC1. Emerging evidence indicates that sildenafil and other phosphodiesterase type 5 inhibitors may enhance the sensitivity of certain types of cancer to standard chemotherapeutic drugs.
多药耐药(MDR)现象降低了癌症化疗成功的希望。ATP 结合盒(ABC)转运体超家族是最大的跨膜家族。ABC 转运体的过度表达是体外和体内癌细胞多药耐药的主要决定因素。不幸的是,直到最近,用于克服 ABC 转运体介导的 MDR 的大多数策略都收效甚微。理想的 MDR 调节剂应该是一种不易引起毒性并改变抗肿瘤药物药代动力学特征的调节剂。西地那非,一种 cGMP 特异性磷酸二酯酶 5 的抑制剂,被发现可显著逆转 ABC 转运体介导的 MDR。我们的结果表明,西地那非对 ABC 转运体具有不同的抑制作用:它显著降低了 ABCB1 和 ABCG2 的外排活性,但对 ABCC1 没有显著影响。新出现的证据表明,西地那非和其他磷酸二酯酶 5 抑制剂可能增强某些类型的癌症对标准化疗药物的敏感性。